Die Allergische Rhinitis als Allergie vom Typ I (Soforttyp) ist nicht nur in Deutschland und Europa weit verbreitet, sondern eine weltweit auftretende Erkrankung. Als Verursacher werden neben bereits bekannten Aeroallergenen wie Hausstaubmilben, Gräser oder Pollen auch luftgetragene Algen diskutiert, die als möglichen Mechanismus über eine T-Zell-abhängige Stimulation Antigen-bindender B-Zellen zur IgE-Produktion führen. Diese Arbeit befasst sich mit der Untersuchung des allergenen Potentials der luftgetragenen Algenspezies S. bacillaris, T. aeria und X. montanum. Dafür wurden mittels direkter und indirekter Sandwich-ELISA-Verfahren Seren von Patienten mit der Diagnose Allergische Rhinitis oder Idiopathische Rhinitis auf enthaltene IgE-Antikörper getestet, die spezifisch an festphasengebundene Algenproteine binden. Des Weiteren wurden Kompetitionstestungen zur Untersuchung der Kreuzhemmbarkeit der drei Algen sowie SDS-Gelelektrophoresen und Western Blots zur Bestimmung der Molmasse der Algenproteine und zum Nachweis der Spezifität des algenbindenden IgEs durchgeführt. Die Ergebnisse belegen, dass die getesteten Algenproteine in der Lage sind, eine entsprechende Immunantwort mit IgE-Produktion auszulösen. Diese neue Gruppe von Allergenen konnte hinsichtlich der Entstehung einer Allergie vom Soforttyp und der damit verbundenen klinischen Bedeutung bewertet werden.

Allergic and hypersensitivity reactions such as anaphylaxis and asthma exacerbations may occur during air travel. Although the exact incidence of in-flight asthma and allergic emergencies is not known, we have concerns that this subject has not received the attention it warrants. There is a need to provide passengers at risk and airlines with the necessary measures to prevent and manage these emergencies. A review of the epidemiology, management and approaches to prevention of allergic and asthma emergencies during air travel is presented with the goal of increasing awareness about these important, potentially preventable medical events.

No description available.

<p>Pojava alergijskog kontatnog dermatitisa koji nastaje kao komplikacija tokom lečenja hronične venske insuficijencije je dobro poznata. Cilj istraživanja je bio da se kod obolelih od hronične venske insuficijencije utvrdi učestalost kontaktne senzibilizacije ekcemskog tipa, potom da li postoji rizik za nastanak kontaktne senzibilizacije kao i postojanje korelacije između dužine trajanja bolesti i kontaktne senzibilizacije. Hipoteza rada je da osobe sa hroničnom venskom insuficijencijom značajno če&scaron;će razvijaju kontaktnu senzibilizaciju nego osobe bez hronične venske insuficijencije, da imaju veći rizik za nastanak kontaktne senzibilizacije kao i da je učestalost kontaktne senzibilizacije u pozitivnoj korelaciji sa dužinom trajanja bolesti. Istraživanje je sprovedeno nad 266 ispitanika. Formirane su dve grupe. Eksperimentalnu grupu su činili oboleli od hronične venske insuficijencije upućeni na alergolo&scaron;ko testiranje pod sumnjom na postojanje kontaktnog dermatitisa, a kontrolnu grupu su činili bolesnici bez hronične venske insuficijencije epikutano testirani pod sumnjom na postojanje kontaktnog dermatitisa. Obolelima od hronične venske insuficijencije je procenjena težina bolesti na osnovu CEAP klasifikacije. Potom je svaki ispitanik podvrgnut alergolo&scaron;kom epikutanom testiranju pač testom. Istraživanje je pokazalo da je učestalost kontaktne senzibilizacije među obolelima od hronične venske insuficijencije iznosila 49,3%. Učestalost kontaktne senzibilizacije kod osoba sa hroničnom venskom insuficijencijom na alergene: iz sastava Evropske standardne baterije je iznosila 31,55%; baterije specifične za hroničnu vensku insuficijenciju je iznosila 28,45%; komercijalno dostupne baterije alergena ubikvitarnih korovskih biljaka iz porodice Compositae je iznosila 6,69%; originalno spravljene ekstrakte ubikvitarnih korovskih biljaka Vojvodine je iznosila 6,11%. Ne postoji statistički značajna razlika u odnosu na pol. Prevalencija kontaktne senzibilizacije kod osoba sa hroničnom venskom insuficijencijom se nije statistički značajno razlikovala od osoba koje nisu imale hroničnu vensku insuficijenciju. Pozitivnost epikutanog alergolo&scaron;kog testa kojim se potvrđuje postojanje kontaktne senzibilizacije je bila statistički značajno vi&scaron;a kod osoba sa hroničnom venskom insuficijencijom. Osobe sa hroničnom venskom insuficijencijom su imale 2,45 puta vi&scaron;i rizik za nastajanje kontaktne senzibilizacije na dva i vi&scaron;e alergena, a 3,69 puta vi&scaron;i rizik za nastajanje kontaktne senzibilizacije na pet i vi&scaron;e alergena u odnosu na one bez hronične venske insuficijencije. Učestalost kontaktne senzibilizacije je u pozitivnoj korelaciji sa dužinom trajanja bolesti.</p> / <p>Development of allergic contact dermatitis as a complication of treatment of chronic venous insufficiency is well known. The aim of this study was to determine the incidence of eczematous contact sensitization in patients with chronic venous insufficiency, possible risks for the development of contact sensitization, and the correlation between disease duration and contact sensitization. The working hypothesis was that the incidence of contact sensitivity is significantly higher in individuals with chronic venous insufficiency than in those without chronic venous insufficiency, that they are at greater risk of developing contact sensitization, and that there is a positive correlation between the incidence of contact sensitization and the disease duration. The study included 266 patients. They were divided into two groups: the study group included patients with chronic venous insufficiency referred for allergy testing due to suspected contact dermatitis, and the control group included patients without chronic venous insufficiency patch tested for suspected contact dermatitis. The severity of chronic venous insufficiency was assessed by CEAP classification. Thereafter, each patient underwent patch testing. The research has shown that the incidence of contact sensitization among patients with chronic venous insufficiency was 49.3%. In these patients, the incidence of contact sensitization to the European standard battery of allergens was 31.55%; to the battery specific for chronic venous insufficiency it was 28.45%; to commercially available batteries of allergens of ubiquitous plants from the Compositae family it was 6.69%; and to originally prepared extracts of ubiquitous plants found in Vojvodina it was 6.11%. There was no statistically significant difference in relation to sex. The prevalence of contact sensitization in patients with chronic venous insufficiency was not significantly different from those without chronic venous insufficiency. Positive patch test reaction rates, confirming the existence of contact sensitization, were significantly higher in patients with chronic venous insufficiency. Patients with chronic venous insufficiency had a 2.45-fold higher risk for developing contact sensitization to two or more allergens, and a 3.69-fold higher risk for developing contact sensitization to five or more allergens compared to those without chronic venous insufficiency. There was a positive correlation between the incidence of contact sensitization and the duration of the disease.</p>

Alors que la rhinite a un fort impact sur la santé publique, chez l’adulte, il n’existe pas de définition standardisée de la rhinite dans les études épidémiologiques. De plus, les facteurs environnementaux de la rhinite sont mal connus et, en particulier, il existe très peu d'études sur les effets à long terme de la pollution atmosphérique sur la rhinite chez l'adulte. Pour combler ces lacunes, nous avons utilisé les données de deux études épidémiologiques multicentriques européennes ayant des données détaillées sur la santé respiratoire et d'exposition annuelle individuelle à la pollution atmosphérique. Nos résultats ont montré que pour mieux caractériser la rhinite, il faut considérer l’ensemble des caractéristiques des symptômes nasaux, les comorbidités et la sensibilisation allergique, et ne pas limiter la maladie à une question ou à un test de sensibilisation allergique. Nous n'avons trouvé aucune association entre la pollution atmosphérique à long terme et l'incidence de la rhinite, mais nous avons montré que l'exposition à long terme à la pollution était associée à une augmentation de la sévérité de la rhinite, soulignant le besoin de contrôler les niveaux de pollution atmosphérique. / Whereas rhinitis has an important public health impact, in adults there is no standardized definition of rhinitis in epidemiological studies. Furthermore, environmental factors of rhinitis are barely known, and in particular, there are very few studies on the effects of long-term exposure to air pollution on rhinitis in adults. To fill these gaps, we used data from two European multicentre epidemiological studies with extensive data on respiratory health and individual estimated exposures to long-term air pollution. Our findings showed that to better characterize rhinitis, one need to consider together all the characteristics of the nasal symptoms, the comorbidities and the allergic sensitization, and not to restrict the disease to one question or one allergic sensitization test. We found no association between long-term air pollution and incidence of rhinitis, but we showed that long-term exposure to air pollution is associated to an increased severity of rhinitis, emphasising that air pollution needs to be controlled.

No description available.

Background: It is unclear how far the superior efficacy of omalizumab, established in randomized controlled clinical trials of patients with severe allergic asthma (SAA), translates into routine practice and when compared to matched controls. Methods: New-onset omalizumab-treated (OT) patients with SAA (n = 53) were compared to a matched control group of usual-care (UC) patients (n = 53). Treatment and procedures were naturalistic. Subsequent to a baseline assessment, patients were followed up over at least 6 months with at least two follow-up assessments. Primary clinical outcomes were the number of asthma attacks, persistence of asthma symptoms and degree of control [asthma control test (ACT), Global Initiative for Asthma]. Secondary outcome criteria were quality of life (Euro-Qol 5D) and number of medications. For each outcome we compared within-group effects from baseline to 6-month follow-up as well as between-group effects. Results: OT patients showed significant improvements in number [effect size (ES) = 0.03] and frequency (ES = 0.04) of asthma attacks as well as asthma control (ES = 0.09), whereas controls revealed no significant improvements in these measures. Further improvements in the OT group were found for ‘perceived control always’ (ACT, p = 0.006), no impairment (ACT, p = 0.02), reduction of sickness days (p = 0.002) and number of medications needed (p = 0.001). Conclusions: Substantial beneficial effects of omalizumab, similar to those observed in controlled trials and after marketing studies, were confirmed, particularly with regard to the reduction of asthma attacks, persistence of symptoms, asthma control and reduction of concomitant asthma medications. This study provides a tougher test and generalizable evidence for the effectiveness of omalizumab in routine care.

Bakgrund: Allergisk rinit (AR) är en vanlig kronisk sjukdom. AR innebär allergi mot luftburna allergener vilket kan yttra sig med långvariga eller återkommande symtom från näsa och/eller ögon med varierande svårighetsgrad. Hälsorelaterad livskvalitet (HRQoL) är de delar av livet som påverkas av hälsa, sjukdom och behandling. Personer med AR som söker vård kan ha svårare symtom och behöver stöd i primärvården. Syfte: Att belysa hälsorelaterad livskvalitet hos personer med allergisk rinit. Metod: Designen var en litteraturstudie bestående av 16 kvantitativa artiklar. Resultat: Samtliga studier fann att personer med svårare AR skattade sin HRQoL sämre än personer med mildare AR. De områden av HRQoL som var påverkade vid svårare AR var dagliga aktiviteter (arbete/skola, hem och hushåll, socialt liv och fritidsaktiviteter), sömn och psykisk hälsa. Gällande psykisk hälsa påvisades sänkt sinnesstämning i form av nedstämdhet, depressiva symtom, ångest och andra känslolägen. Slutsats: Resultatet är entydigt, personer med svårare AR skattar sämre HRQoL än de med mildare sjukdom inom olika områden såsom dagliga aktiviteter, sömn och psykisk hälsa. Resultatet kan bidra med större förståelse om patienter med AR och vara av värde för hälsooch sjukvården där distriktssköterskor med sin specialistkunskap och förskrivningsrätt kan spela en betydelsefull roll. Genom ökad förståelse kan omhändertagandet av patienter med AR förbättras med mål att ge stöd för bättre HRQoL och att patienten ska må bra i sin sjukdom. / Background: Allergic rhinitis (AR) is a common chronic disease. AR means allergy to airborne allergens, which can manifest itself with long-term or recurring symptoms from the nose and/or eyes with varying degrees of severity. Health-related quality of life (HRQoL) is areas of life that are affected by health, disease and treatment. People with AR that seek medical care may have more severe symptoms and need support from primary care. Aim: To highlight health-related quality of life in people with allergic rhinitis. Method: The design was a general literature review of 16 quantitative articles. Results: All studies found that people with more severe AR rated their HRQoL worse than people with mild AR. The areas of health-related quality of life that were affected in more severe AR were daily activities (work/school, home and household, social life and leisure activities), sleep and mental health. In the area mental health associations were seen with affected mood such as sadness, depressive symptoms, anxiety and other emotional states. Conclusion: The result is unanimously, people with more severe AR rated worse HRQoL than people with mild disease in various areas such as daily activities, sleep and mental health. The result can contribute to a greater understanding of patients with AR and be of value to the healthcare system, where district nurses with their specialist knowledge and right to prescribe medication can play an important role. Through increased understanding, the care of patients with AR can be improved with the aim of providing support for better HRQoL and better wellbeing.

No description available.

No description available.